S. Lapointe

Group V secreted phospholipase A2 contributes to LPS‐induced leukocyte recruitment

J. Tanguay, S. Lapointe, A. Brkovic, 2010, Journal of cellular physiology.

Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.

C. Labrie, F. Labrie, M. Plante, 1987, Journal of steroid biochemistry.

Sera from patients with autoimmune disease recognize conformational determinants on the 60-kd Ro/SS-A protein.

S. Lapointe, H. Ménard, G. Boire, 1991, Arthritis and rheumatism.

HIF2α reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma

J. Favier, S. Lapointe, M. Sirois, 2007, BMC Cancer.

Discovery and Pharmacological Characterization of a Small-Molecule Antagonist at Neuromedin U Receptor NMUR2

S. Trivedi, Jian Huang, Jay Liu, 2009, Journal of Pharmacology and Experimental Therapeutics.

Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03

L. Moulton, F. Polack, Marc‐André D'Aoust, 2022, medRxiv.

Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice.

F. Labrie, M. Plante, S. Lapointe, 1988, Journal of steroid biochemistry.

Angiopoietins-1 and -2 are both capable of mediating endothelial PAF synthesis: intracellular signalling pathways.

S. Lapointe, A. Brkovic, M. Sirois, 2006, Cellular signalling.

Specific induction of a functional endogenous D2 short dopamine receptor in GH4C1 cells.

S. Lapointe, P. Falardeau, S. Allard, 1993, Biochemical and biophysical research communications.